HER2DX Genomic Testing Outperforms Traditional Histopathology in Predicting Neoadjuvant Therapy Response for HER2-Positive Breast Cancer
Evolution of Precision Medicine in HER2-Positive Breast Cancer
The management of HER2-positive (HER2+) breast cancer has undergone a radical transformation over the last two decades. Once associated with a poor prognosis, the advent of HER2-targeted therapies has significantly improved survival outcomes. However, HER2+ breast cancer remains a highly heterogeneous disease. While some patients achieve a pathologic complete response (pCR) with standard trastuzumab-based regimens, others require more intensive treatment or experience early relapse. Traditional biomarkers, such as hormone receptor (HR) status, tumor grade, and the Ki67 proliferation index, provide valuable but incomplete information regarding the biological behavior of these tumors.
The Emergence of HER2DX
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.